CASPOCIP caspofungin (as acetate) 50 mg powder for injection vial

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

caspofungin acetate, Quantity: 55.49 mg (Equivalent: caspofungin, Qty 50 mg)

Verfügbar ab:

Cipla Australia Pty Ltd

Darreichungsform:

Injection, powder for

Zusammensetzung:

Excipient Ingredients: sucrose; mannitol; glacial acetic acid; sodium hydroxide

Verabreichungsweg:

Intravenous

Anwendungsgebiete:

CASPOCIP is indicated for: ? Empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics ? Treatment of: - Invasive Candidiasis, including candidaemia - Oesophageal Candidiasis - Invasive Aspergillosis in patients who are refractory to or intolerant of other therapies

Produktbesonderheiten:

Visual Identification: White to off white powder or cake; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store at 2 to 8 degrees Celsius

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2018-01-12